Loading…
Loading…
EQUITY / NASDAQ · XNGS
Cumberland Pharmaceuticals Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗7.83 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 7.83 USD · Volume 9,963
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Cash and cash equivalents | 3,862,402 USD | — | — |
| Net income | -4,276,377 USD | — | — |
| Operating profit | -3,160,461 USD | — | — |
| Revenue | 8,801,241 USD | — | — |
| Total assets | 62,879,694 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,862,402 USD | — | — | 11,444,693 USD | 11,444,693 USD | — | — | — |
| Net incomeIncome statement | -4,276,377 USD | -7,566,016 USD | -3,287,051 USD | — | -1,411,692 USD | -2,836,128 USD | -1,940,764 USD | -1,424,436 USD |
| Operating profitIncome statement | -3,160,461 USD | -6,092,831 USD | — | — | -1,371,202 USD | -2,791,993 USD | -1,965,260 USD | -1,420,791 USD |
| RevenueIncome statement | 8,801,241 USD | 17,932,559 USD | — | — | 13,678,651 USD | 44,521,431 USD | 8,292,362 USD | 30,842,780 USD |
| Total assetsBalance sheet | 62,879,694 USD | — | — | 76,823,992 USD | 76,823,992 USD | — | — | — |
| Total equityBalance sheet | 17,438,013 USD | — | 21,303,012 USD | 24,880,322 USD | 24,880,322 USD | — | — | — |
| Total liabilitiesBalance sheet | 45,773,246 USD | — | — | 52,279,770 USD | 52,279,770 USD | — | — | — |
| Capital expendituresCash flow statement | — | 38,283 USD | — | — | — | 97,903 USD | — | 97,904 USD |
| Financing cash flowCash flow statement | — | -6,150,465 USD | — | — | — | -6,745,516 USD | — | -6,063,778 USD |
| Investing cash flowCash flow statement | — | -1,987,591 USD | — | — | — | -4,706,497 USD | — | -1,633,159 USD |
| Operating cash flowCash flow statement | — | 555,765 USD | — | — | — | 4,932,522 USD | — | 4,929,498 USD |
| Report source | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 08/07/2026 | Open report ↗ Published: 03/09/2026 | Open report ↗ Published: 03/09/2026 | Open report ↗ Published: 03/09/2026 | Open report ↗ Published: 11/07/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.